Table 1:

DTI parameters in healthy controls, the total cohort of patients with myelitis, and different subgroups

Healthy ControlsAll Patients with or without Active LesionsPatients without Active LesionsPatients with Active Lesions
Patients with MS and Other PatientsaPatients with MSOther Patientsa
No.12403420146
Sex (F/M)7:519:2118:169:119:51:5
Age (yr) (mean)31.6 ± 9.143.3 ± 12.043.6 ± 11.840.5 ± 13.048.0 ± 7.541.5 ± 14.7
FA (mean)0.61 ± 0.010.54 ± 0.060.52 ± 0.050.54 ± 0.040.50 ± 0.050.64 ± 0.05
MD (10−3 mm2/s) (mean)1.17 ± 0.071.30 ± 0.281.38 ± 0.221.40 ± 0.201.34 ± 0.250.84 ± 0.13
E1 = aD (10−3 mm2/s) (mean)1.96 ± 0.102.02 ± 0.362.12 ± 0.282.17 ± 0.252.04 ± 0.321.45 ± 0.17
E2 (10−3 mm2/s) (mean)0.92 ± 0.051.10 ± 0.271.18 ± 0.221.18 ± 0.201.18 ± 0.250.68 ± 0.12
E3 (10−3 mm2/s) (mean)0.63 ± 0.060.77 ± 0.240.83 ± 0.190.84 ± 0.170.82 ± 0.230.39 ± 0.13
rD (10−3 mm2/s) (mean)0.77 ± 0.050.93 ± 0.261.00 ± 0.201.00 ± 0.191.00 ± 0.230.53 ± 0.12
Ratiob (mean)2.5 ± 0.082.25 ± 0.372.15 ± 0.252.20 ± 0.262.09 ± 0.222.82 ± 0.45
  • a Patients with myelitis with other causes of inflammatory myelopathy (neuromyelitis optica, sarcoidosis, Gougerot-Sjögren syndrome, idiopathic).

  • b Ratios of aD and rD.